Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan, Fludarabine, and Thiotepa for Allogeneic HCT in Non-Malignant Disorders
NCT03980769Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2021
- Primary completion
- Jul 2028
- Modality
- DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan, fludarabine and thiotepa in Non-neoplastic hematopoietic and lymphoid cell disorder, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Engraftment failure at 1 year. Started May 2021; status: recruiting.
02
Drugs
treosulfanfludarabinethiotepa
03
Conditions
Non-neoplastic hematopoietic and lymphoid cell disorder
Beyond the preview
Go deeper on NCT03980769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03980769.